drugset
drugset / Trial / NCT04923152

Effective Dose of Statin Post PCI

NCT04923152 ↗

Completed 582 enrolled Shiraz University of Medical Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this study post coronary stenting patients, were enrolled to receive moderate dose versus high dose statin for 1 year, and the result of major adverse cardiovascular events were recorded

Timeline

Start
2020-01-01
Primary completion
2021-01-01
Completion
2021-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 5 mg —
Subject Rosuvastatin Small molecule 40 mg —

Indications

No indication recorded.